Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from BioNTech

US Covid vaccine maker Moderna suing rivals Pfizer and BioNTech over jab

The company said it believes its rivals’ vaccine infringes on patents Moderna filed between 2010 and 2016

Wales Online

Pfizer asks EU drug regulator to OK tweaked COVID vaccine

Pharmaceuticals Pfizer and BioNTech say they have asked the European Medicines Agency to authorize their updated coronavirus booster vaccine that includes the most recent omicron subvariants

The Independent UK

Moderna sues Pfizer over COVID-19 vaccine patents

The vaccine maker alleges that its rivals Pfizer and BioNTech used some patented features of its mRNA technology to develop their COVID vaccines.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna sues Pfizer and BioNTech over Covid-19 vaccine

The vaccine maker said it had filed patent infringement lawsuits in the US and Germany.

The Independent UK

Moderna sues Pfizer/BioNTech alleging patent infringement over Covid vaccine

Moderna seeks unspecified damages in lawsuit over rivals’ jab

Evening Standard

Covid infections at lowest level in two months- ONS

High levels of coronavirus antibodies among the population means the rate of serious illness remains low

Evening Standard

Moderna sues Pfizer, BioNTech for Covid-19 vaccine patent infringement

Washington (AFP) - Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.

AFP

Read news from The Economist, FT, and more,
with one subscription

The Covid Gambit: Pfizer, Moderna Struggle To Get The Jump On Covid

Companies are working to develop updated Covid boosters. Will they be too late to make a difference for the vaccine stocks — and society?

Investors Business Daily

Moderna sues Pfizer, BioNTech over COVID vaccine technology

Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their COVID-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans.

Tribune News Service

Moderna sues Pfizer over Covid vaccine

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first Covid-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

Bangkok Post

Moderna Signals End Of Pandemic By Suing Pfizer, BioNTech Over Covid Shots

Moderna is suing Pfizer and BioNTech for patent infringement, claiming the duo copied its mRNA technology. All three vaccine stocks fell.

Investors Business Daily

Moderna sues Pfizer over patents behind COVID-19 vaccine

COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology in order to make their own vaccine

The Independent UK

Moderna sues Pfizer-BioNTech accusing them of copying Covid shot technology

‘We believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permission,’ Moderna legal officer says

The Independent UK

Moderna Sues Pfizer, BioNtech For Covid Vaccine Patent Infringement

"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission," Moderna said.

The Street

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Moderna sues Pfizer, BioNTech over COVID-19 vaccine

The lawsuit seeks unspecified monetary damages for patent infringement.

WEKU

Pfizer asks FDA to greenlight new omicron booster shots, which could arrive this fall

Pfizer has submitted data on its bivalent COVID-19 booster shot that specifically targets the latest omicron subvariants. If authorized, the company says the shots could be ready as soon as September.

Investors Business Daily

Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions

The Biden administration is planning to stop paying for Covid vaccines and treatments, a move that could buoy some Covid stocks.

AFP

EU eyes autumn approval of Pfizer jab for Covid variants

The Hague (AFP) - The EU's medicines watchdog said Wednesday it aims to approve this autumn a Pfizer/BioNTech Covid vaccine adapted for two fast-spreading subvariants of the Omicron strain.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

BioNTech Whale Trades For August 09

A whale with a lot of money to spend has taken a noticeably bullish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 10 strange trades.

Investors Business Daily

BioNTech Dives As Pfizer Partner Reports Lagging Covid Vaccine Sales, Guidance

BioNTech lagged second-quarter expectations and issued light 2022 guidance on Monday, leading BNTX stock to dive.

The Independent UK

BioNTech reports strong first half, expects demand to grow

BioNTech, which teamed with Pfizer to develop the first widely used COVID-19 vaccine, has reported higher revenue and net profit in the first half of the year

Benzinga

Benzinga Before The Bell: Elon Musk Confirms Tesla AI Day Part 2, Dogecoin Scam, BioNTech Q2 Earnings Shocker And Other Top Financial Stories Monday, August 8

CNBC Celsius Withdraws Motion To Rehire CFO

Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Pfizer (PFE), BioNTech Seek EU Nod For Omicron-Based COVID Jab

Pfizer (NYSE: PFE) and its partner, BioNTech (NASDAQ: BNTX) announced that they have completed the submission of a regulatory application to the European Medicines Agency (EMA), which seeks authorization for thei

Investors Business Daily

Why 'Covid Fatigue' Isn't Enough To Keep BioNTech Down; Shares Surge On Upgrade

BioNTech snagged an upgrade Wednesday with an analyst saying "Covid fatigue" has obscured its non-pandemic efforts.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.